NCT02494258 2026-04-02A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological DisordersCelgenePhase 2 Completed5 enrolled 10 charts
NCT05197426 2026-02-11A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete RemissionBristol-Myers SquibbPhase 2 Active not recruiting19 enrolled 24 charts
NCT05413018 2025-12-08An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete RemissionBristol-Myers SquibbPhase 2 Active not recruiting34 enrolled
NCT02223052 2020-05-12Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCelgenePhase 1 Completed89 enrolled
NCT00528983 2019-11-08Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous LeukemiaCelgenePhase 1 Completed133 enrolled
NCT01835587 2018-11-20Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).CelgenePhase 1/2 Completed31 enrolled 30 charts
NCT01908387 2015-07-28Phase 1 Study of CC-486 in Japanese Subjects With Hematological NeoplasmsCelgenePhase 1 Terminated2 enrolled